S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$7.38
-0.09 (-1.20%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.31
$7.61
50-Day Range
$6.41
$10.00
52-Week Range
$1.05
$10.02
Volume
134,105 shs
Average Volume
380,456 shs
Market Capitalization
$455.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.71

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
45.2% Upside
$10.71 Price Target
Short Interest
Healthy
5.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Avadel Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$53,400 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

465th out of 1,054 stocks

Pharmaceutical Preparations Industry

229th out of 517 stocks


AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
AVDL Avadel Pharmaceuticals plc
Avadel: Lumryz Overhang Now Removed, Rate Buy
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Needham Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
11/09/2022
Today
1/29/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$10.71
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+45.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-77,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
$1.33 per share

Miscellaneous

Free Float
59,802,000
Market Cap
$455.94 million
Optionable
Optionable
Beta
1.67

Social Links


Key Executives

  • Mr. Gregory J. Divis Jr. (Age 56)
    CEO & Director
    Comp: $862.59k
  • Mr. Thomas S. McHugh (Age 58)
    Sr. VP & CFO
    Comp: $550k
  • Mr. Richard Kim (Age 54)
    Chief Commercial Officer
    Comp: $596.3k
  • Mr. Jerad G. Seurer
    Gen. Counsel & Company Sec.
  • Mr. Gregory J. Davis (Age 58)
    VP of Corp. and Bus. Devel.
  • Mr. Mark W. Elrod
    VP of Sales
  • Ms. Angie Woods
    VP of People & Culture
  • Mr. Christian Kalita Pharm.D
    Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan (Age 58)
    VP of Sales & Marketing and Head of Commercial Operations
  • Dr. Jordan S. Dubow M.D. (Age 45)
    Consultant













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2023?

6 brokers have issued twelve-month price targets for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they expect the company's share price to reach $10.71 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2023?

Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 3.1% and is now trading at $7.38.
View the best growth stocks for 2023 here
.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totaling 3,340,000 shares, a drop of 17.5% from the December 31st total of 4,050,000 shares. Based on an average trading volume of 614,300 shares, the days-to-cover ratio is currently 5.4 days. Currently, 5.9% of the company's stock are sold short.
View Avadel Pharmaceuticals' Short Interest
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.11.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Edge Wealth Management LLC (0.28%) and Aaron Wealth Advisors LLC (0.02%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $7.38.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $455.94 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 1/29/2023 by MarketBeat.com Staff